v3.26.1
Segment Reporting (Q1) (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 04, 2026
USD ($)
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting          
Number of reportable segments | segment   1   1  
Research and development          
Total research and development expenses   $ 4,093 $ 7,737 $ 23,276 $ 40,179
General and administrative          
Total general and administrative expenses   4,787 6,085 19,875 24,988
Impairment of long-lived assets     2,637 6,145 5,233
Net gain on lease termination $ 600 633      
Loss from operations   8,247 16,459 49,296 70,400
Other (income) expense, net   (688) (1,054) (3,774) (5,633)
Net loss   7,559 15,405 45,522 64,767
Genetic Medicines Segment          
Research and development          
Wages, benefits, and other payroll   1,458 3,589 7,462 12,265
Third-party costs   2,432 3,794 14,532 22,691
Share-based compensation   142 244 842 2,529
Depreciation and amortization   61 110 440 2,694
Total research and development expenses   4,093 7,737 23,276 40,179
General and administrative          
Wages, benefits, and other payroll   1,891 2,790 7,784 9,255
Third-party costs   2,415 2,603 9,644 12,055
Share-based compensation   414 614 2,159 3,291
Depreciation and amortization   67 78 288 387
Total general and administrative expenses   4,787 6,085 19,875 24,988
Impairment of long-lived assets     2,637 6,145 5,233
Net gain on lease termination   (633)      
Loss from operations   (8,247) (16,459) 49,296 70,400
Other (income) expense, net   688 1,054 (3,774) (5,633)
Net loss   $ (7,559) $ (15,405) $ 45,522 $ 64,767